Global Manufacturing of CAR T Cell Therapy

Molecular Therapy Methods and Clinical Development

Volumn 4, Issue , 2017, Pages 92-101

  Levine, Bruce L ^a   Miskin, James ^b   Wonnacott, Keith ^c   Keir, Christopher ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b OXFORD BIOMEDICA UK LTD   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

chimeric antigen receptor; global regulatory environment; lentiviral vector; manufacturing; T lymphocytes

Indexed keywords

AUTOANTIGEN; CHIMERIC ANTIGEN RECEPTOR; LENTIVIRUS VECTOR; TISAGENLECLEUCEL T;

CELL THERAPY; CLINICAL TRIAL (TOPIC); DOWNSTREAM PROCESSING; DRUG MANUFACTURE; DRUG QUALITY; DRUG SAFETY; EXPECTATION; FOLLOW UP; HUMAN; LONG TERM CARE; NONHUMAN; POPULATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VECTOR CONTROL;

EID: 85015643317     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1016/j.omtm.2016.12.006     Document Type: Review

References (62)

1. 1 Kuwana, Y., Asakura, Y., Utsunomiya, N., Nakanishi, M., Arata, Y., Itoh, S., Nagase, F., Kurosawa, Y., Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem. Biophys. Res. Commun. 149 (1987), 960–968.
2. 2 Gross, G., Waks, T., Eshhar, Z., Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. USA 86 (1989), 10024–10028.
3. 3 Finney, H.M., Lawson, A.D., Bebbington, C.R., Weir, A.N., Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161 (1998), 2791–2797.
4. 4 Maher, J., Brentjens, R.J., Gunset, G., Rivière, I., Sadelain, M., Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat. Biotechnol. 20 (2002), 70–75.
5. 5 Sadelain, M., Brentjens, R., Rivière, I., The basic principles of chimeric antigen receptor design. Cancer Discov. 3 (2013), 388–398.
6. 6 Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
7. 7 Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med., 6, 2014, 224ra25.
8. 8 Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385 (2015), 517–528.
9. 9 Maude, S.L., Pulsipher, M.A., Boyer, M.W., Grupp, S.A., Davies, S.M., Phillips, C.L., Verneris, M.R., August, K.J., Schlis, K., Driscoll, T.A., et al. Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed/refractory acute lymphoblastic leukemia: results of an interim analysis. Blood, 128, 2016, 2801.
10. 10 Grupp, S.A., Laetsch, T.W., Buechner, J., Bittencourt, H., Maude, S.L., Verneris, M.R., Myers, G.D., Boyer, M.W., Rives, S., De Moerloose, B., et al. Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood, 128, 2016, 221.
11. 11 Levine, B.L., Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Ther. 22 (2015), 79–84.
12. 12 Smith, J.W., Apheresis techniques and cellular immunomodulation. Ther. Apher. 1 (1997), 203–206.
13. 13 Lee, G., Arepally, G.M., Anticoagulation techniques in apheresis: from heparin to citrate and beyond. J. Clin. Apher. 27 (2012), 117–125.
14. 14 Powell, D.J. Jr., Brennan, A.L., Zheng, Z., Huynh, H., Cotte, J., Levine, B.L., Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program. Cytotherapy 11 (2009), 923–935.
15. 15 Riddell, S.R., Sommermeyer, D., Berger, C., Liu, L.S., Balakrishnan, A., Salter, A., Hudecek, M., Maloney, D.G., Turtle, C.J., Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J. 20 (2014), 141–144.
16. 16 Levine, B.L., Bernstein, W.B., Connors, M., Craighead, N., Lindsten, T., Thompson, C.B., June, C.H., Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol. 159 (1997), 5921–5930.
17. 17 Suhoski, M.M., Golovina, T.N., Aqui, N.A., Tai, V.C., Varela-Rohena, A., Milone, M.C., Carroll, R.G., Riley, J.L., June, C.H., Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol. Ther. 15 (2007), 981–988.
18. 18 Levine, B.L., Personalized cell-based medicine: activated and expanded T cells for adoptive immunotherapy. BioProcessing J. 6 (2007), 14–19.
19. 19 Hami, L.S., Green, C., Leshinsky, N., Markham, E., Miller, K., Craig, S., GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL. Cytotherapy 6 (2004), 554–562.
20. 20 Somerville, R.P., Dudley, M.E., Bioreactors get personal. OncoImmunology 1 (2012), 1435–1437.
21. 21 Maus, M.V., Thomas, A.K., Leonard, D.G., Allman, D., Addya, K., Schlienger, K., Riley, J.L., June, C.H., Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol. 20 (2002), 143–148.
22. 22 Guedan, S., Chen, X., Madar, A., Carpenito, C., McGettigan, S.E., Frigault, M.J., Lee, J., Posey, A.D. Jr., Scholler, J., Scholler, N., et al. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood 124 (2014), 1070–1080.
23. 23 Coffin, J., Hughes, S., Varmus, H., Retroviruses. 1997, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
24. 24 McGarrity, G.J., Hoyah, G., Winemiller, A., Andre, K., Stein, D., Blick, G., Greenberg, R.N., Kinder, C., Zolopa, A., Binder-Scholl, G., et al. Patient monitoring and follow-up in lentiviral clinical trials. J. Gene Med. 15 (2013), 78–82.
25. 25 Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C.C., Ranzani, M., Benedicenti, F., Sergi, L.S., Ambrosi, A., Ponzoni, M., et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 119 (2009), 964–975.
26. 26 Huls, M.H., Figliola, M.J., Dawson, M.J., Olivares, S., Kebriaei, P., Shpall, E.J., Champlin, R.E., Singh, H., Cooper, L.J., Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J. Vis. Exp.(72), 2013, e50070.
27. 27 Singh, H., Figliola, M.J., Dawson, M.J., Olivares, S., Zhang, L., Yang, G., Maiti, S., Manuri, P., Senyukov, V., Jena, B., et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS ONE, 8, 2013, e64138.
28. 28 Beatty, G.L., Haas, A.R., Maus, M.V., Torigian, D.A., Soulen, M.C., Plesa, G., Chew, A., Zhao, Y., Levine, B.L., Albelda, S.M., et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2 (2014), 112–120.
29. 29 Aronovich, E.L., McIvor, R.S., Hackett, P.B., The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum. Mol. Genet. 20:R1 (2011), R14–R20.
30. 30 Somerville, R.P.T., Devillier, L., Parkhurst, M.R., Rosenberg, S.A., Dudley, M.E., Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor. J. Transl. Med., 10, 2012, 69.
31. 31 Jin, J., Sabatino, M., Somerville, R., Wilson, J.R., Dudley, M.E., Stroncek, D.F., Rosenberg, S.A., Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J. Immunother. 35 (2012), 283–292.
32. 32 Bajgain, P., Mucharla, R., Wilson, J., Welch, D., Anurathapan, U., Liang, B., Lu, X., Ripple, K., Centanni, J.M., Hall, C., et al. Optimizing the production of suspension cells using the G-Rex “M” series. Mol. Ther. Methods Clin. Dev., 1, 2014, 14015.
33. 33 Kaiser, A.D., Assenmacher, M., Schröder, B., Meyer, M., Orentas, R., Bethke, U., Dropulic, B., Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther. 22 (2015), 72–78.
34. 34 Mock, U., Nickolay, L., Cheung, G., Zhan, H., Peggs, K., Johnston, I., Kaiser, A., Pule, M., Thrasher, A., Qasim, W., Automated lentiviral transduction of T cells with CARs using the CliniMACS Prodigy. Blood, 126, 2015, 2043.
35. 35 Lamers, C.H., van Elzakker, P., Luider, B.A., van Steenbergen, S.C., Sleijfer, S., Debets, R., Gratama, J.W., Retroviral vectors for clinical immunogene therapy are stable for up to 9 years. Cancer Gene Ther. 15 (2008), 268–274.
36. 36 Przybylowski, M., Hakakha, A., Stefanski, J., Hodges, J., Sadelain, M., Rivière, I., Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories. Gene Ther. 13 (2006), 95–100.
37. 37 Kim, V.N., Mitrophanous, K., Kingsman, S.M., Kingsman, A.J., Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J. Virol. 72 (1998), 811–816.
38. 38 Dull, T., Zufferey, R., Kelly, M., Mandel, R.J., Nguyen, M., Trono, D., Naldini, L., A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72 (1998), 8463–8471.
39. 39 Wang, X., Olszewska, M., Qu, J., Wasielewska, T., Bartido, S., Hermetet, G., Sadelain, M., Rivière, I., Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor. J. Immunother. 38 (2015), 127–135.
40. 40 Schambach, A., Zychlinski, D., Ehrnstroem, B., Baum, C., Biosafety features of lentiviral vectors. Hum. Gene Ther. 24 (2013), 132–142.
41. 41 Yu, S.F., von Rüden, T., Kantoff, P.W., Garber, C., Seiberg, M., Rüther, U., Anderson, W.F., Wagner, E.F., Gilboa, E., Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. USA 83 (1986), 3194–3198.
42. 42 Kotsopoulou, E., Kim, V.N., Kingsman, A.J., Kingsman, S.M., Mitrophanous, K.A., A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J. Virol. 74 (2000), 4839–4852.
43. 43 Zufferey, R., Dull, T., Mandel, R.J., Bukovsky, A., Quiroz, D., Naldini, L., Trono, D., Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72 (1998), 9873–9880.
44. 44 Cross, P.J., Levine, B.L., Assays for the release of cellular gene therapy products. Dropulic, B., Carter, B.J., (eds.) Concepts in Genetic Medicine, 2006, John Wiley & Sons, 307–318.
45. 45 Vannucci, L., Lai, M., Chiuppesi, F., Ceccherini-Nelli, L., Pistello, M., Viral vectors: a look back and ahead on gene transfer technology. New Microbiol. 36 (2013), 1–22.
46. 46 Varmus, H.E., Quintrell, N., Ortiz, S., Retroviruses as mutagens: insertion and excision of a nontransforming provirus alter expression of a resident transforming provirus. Cell 25 (1981), 23–36.
47. 47 Shen-Ong, G.L., Potter, M., Mushinski, J.F., Lavu, S., Reddy, E.P., Activation of the c-myb locus by viral insertional mutagenesis in plasmacytoid lymphosarcomas. Science 226 (1984), 1077–1080.
48. 48 Scholler, J., Brady, T.L., Binder-Scholl, G., Hwang, W.T., Plesa, G., Hege, K.M., Vogel, A.N., Kalos, M., Riley, J.L., Deeks, S.G., et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med., 4, 2012, 132ra53.
49. 49 Bear, A.S., Morgan, R.A., Cornetta, K., June, C.H., Binder-Scholl, G., Dudley, M.E., Feldman, S.A., Rosenberg, S.A., Shurtleff, S.A., Rooney, C.M., et al. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?. Mol. Ther. 20 (2012), 246–249.
50. 50 Briefing document—testing for replication competent retrovirus (RCR)/lentivirus (RCL) in retroviral and lentiviral vector based gene therapy products—revisiting current FDA recommendations. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM232592.pdf. Accessed 12 April 2016.
51. 51 Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., June, C.H., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med., 3, 2011, 95ra73.
52. 52 Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., June, C.H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365 (2011), 725–733.
53. 53 Turtle, C.J., Berger, C., Sommermeyer, D., Budiarto, T., Hanafi, L., Melville, K., Pender, B., Steevens, N., Chaney, C., Heimfeld, S., et al. Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition. J. Clin. Oncol., 33, 2015.
54. 54 Lee, D.W., Gardner, R., Porter, D.L., Louis, C.U., Ahmed, N., Jensen, M., Grupp, S.A., Mackall, C.L., Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124 (2014), 188–195.
55. 55 Hoyos, V., Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H.E., Rooney, C.M., Brenner, M.K., Dotti, G., Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24 (2010), 1160–1170.
56. 56 Budde, L.E., Berger, C., Lin, Y., Wang, J., Lin, X., Frayo, S.E., Brouns, S.A., Spencer, D.M., Till, B.G., Jensen, M.C., et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS ONE, 8, 2013, e82742.
57. 57 Di Stasi, A., Tey, S.K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A.G., Grilley, B., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365 (2011), 1673–1683.
58. 58 Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M., Sadelain, M., Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31 (2013), 71–75.
59. 59 Gouble, A., Philip, B., Poirot, L., Schiffer-Mannioui, C., Galetto, R., Derniame, S., Cheung, G., Arnould, S., Desseaux, C., Pule, M., Smith, J., In vivo proof of concept of activity and safety of UCART19, an allogeneic “off-the-shelf” adoptive T-cell immunotherapy against CD19+ B-cell leukemias. Blood, 124, 2014, 4689.
60. 60 Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., et al. Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies. Cancer Res. 75 (2015), 3853–3864.
61. 61 Qasim, W., Jal Amrolia, P., Samarasinghe, S., Ghorashian, S., Zhan, H., Stafford, S., Butler, K., Ahsan, G., Gilmour, K., Adams, S., et al. First clinical application of TALEN engineered universal CAR19 T cells in B-ALL. Blood, 126, 2015, 2046.
62. 62 Long, A.H., Haso, W.M., Shern, J.F., Wanhainen, K.M., Murgai, M., Ingaramo, M., Smith, J.P., Walker, A.J., Kohler, M.E., Venkateshwara, V.R., et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21 (2015), 581–590.